Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred within a week of starting everolimus and an...

Full description

Saved in:
Bibliographic Details
Published inCase reports in transplantation Vol. 2018; no. 2018; pp. 1 - 5
Main Authors Tsunoda, Shirley, Valasek, Mark A., Mendler, Michel H., Patel, Serena
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 2018
Hindawi
John Wiley & Sons, Inc
Hindawi Limited
Wiley
Subjects
Analysis
Angiogenesis inhibitors
Antigens
Case Report
Case reports
Complications and side effects
Drug approval
Drug dosages
Drug therapy
Enzymes
Hepatitis
Inflammation
Kinases
Laboratories
Liver
Liver diseases
Liver transplants
Lymphocytes
Physiological aspects
Product safety
Systematic review
Tacrolimus
Transplantation
Transplants & implants
Timor-Leste
Online AccessGet full text

Cover

More Information
Summary:Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred within a week of starting everolimus and an upward trend in the transaminase levels continued with supporting histopathologic changes confirmed by liver biopsy. Within one week of drug discontinuation, his liver enzymes normalized to baseline. This report includes a brief review of the pharmacokinetic properties of everolimus, a review of the relevant literature, and an analysis using the RUCAM and Naranjo algorithms.
Bibliography:Academic Editor: Piero Boraschi
ISSN:2090-6943
2090-6951
DOI:10.1155/2018/7410508